Navigation Links
Perrigo Company To Present At The Morgan Stanley Global Healthcare Conference
Date:9/7/2012

ALLEGAN, Mich., Sept. 7, 2012 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO; TASE) today announced that Perrigo Chairman, President and CEO Joseph C. Papa will present at the Morgan Stanley Global Healthcare Conference on Monday, September 10, 2012 at the Grand Hyatt Hotel in New York, NY. Interested parties can access the presentation, which is scheduled to begin at 2:25 PM EDT, at http://cc.talkpoint.com/morg007/091112a_mc/?entity=100_SCJCI8I.

From its beginnings as a packager of generic home remedies in 1887, Allegan, Michigan-based Perrigo Company has grown to become a leading global provider of quality, affordable healthcare products. Perrigo develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, dietary supplements and active pharmaceutical ingredients (API). The Company is the world's largest manufacturer of OTC pharmaceutical products for the store brand market. The Company's primary markets and locations of logistics operations have evolved over the years to include the United States, Israel, Mexico, the United Kingdom, India, China and Australia. Visit Perrigo on the Internet (http://www.perrigo.com).

Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections.  While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 30, 2012, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Perrigo Company
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Perrigo Company Announces Quarterly Dividend
2. Perrigo Receives FDA Approval And Commences Launch Of Clobetasol Propionate Shampoo, 0.05%
3. Perrigo Company To Present At The William Blair Growth Stock Conference
4. Perrigo Announces FDA Final Approval Of Tris Pharmas Dextromethorphan Polistirex Extended-Release Oral Suspension
5. Perrigo Receives FDA Approval for Butoconazole Nitrate 2% Vaginal Cream
6. Perrigo Announces FDA Final Approval and Launch of Store Brand OTC Lansoprazole 15mg Capsules
7. Perrigo Company to Present at the Bank of America Merrill Lynch 2012 Healthcare Conference
8. Perrigo Reports Record Third Quarter Revenue And Earnings And Raises Full Year EPS Guidance
9. Perrigo Company Will Release Third Quarter Fiscal 2012 Results On May 8, 2012
10. Actinium Pharmaceuticals Commences Screening for the Second Cohort of Patients in the Companys Ongoing Phase I/II Trial in Acute Myeloid Leukemia
11. Medical Alarm Provides Investor Update -- Company Surpassing Previous Record Order Levels as Consumer Interest Accelerates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... , January 18, 2017 Ximbio, ... to share research resources, has opened its first North American ... ... marks an expansion for Ximbio following its launch in October ... Research Technology (CRT), the commercialization arm of the foundation Cancer ...
(Date:1/18/2017)... , Jan. 18, 2017  Astellas Pharma Inc. ... ) today announced its participation in Access Accelerated, ... non-communicable disease (NCD) prevention, diagnostics and treatment in ... other leading pharmaceutical companies and in collaboration with ... International Cancer Control (UICC), Astellas will work towards ...
(Date:1/17/2017)... -- Secretary of Health Dr. Karen Murphy ... are warning Pennsylvanians of the potentially lethal risks ... the drug in Beaver County . ... animals and is not meant for humans – it ... it," Secretary Murphy said. "It,s absolutely essential that first ...
Breaking Medicine Technology:
(Date:1/18/2017)... ... January 18, 2017 , ... The Hear the World ... with the donation of cochlear implants. In February 2017, the first three children ... fair chance of leading an independent life. This engagement builds on the support ...
(Date:1/17/2017)... ... 2017 , ... Anesthesia Progress – Everyone wants less pain during ... option for each patient. Dentists have several general anesthesia alternatives and finding the right ... the Tokyo Dental College in Tokyo, Japan wanted to find out which anesthetic was ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... , The company, owned and operated by Ed Stroup, was created to ... price with the highest level of customer service. Healthful Balance products can be ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... Palm Desert, is opening a new office in San Clemente, California this month. ... (dTMS) in Southern California, successfully treating individuals struggling with major depression. Depression impacts ...
(Date:1/17/2017)... CA (PRWEB) , ... January 17, 2017 , ... A ... named winners of the fourth Cradle to Cradle Product Design Challenge , the ... fourth in a series of six circular design challenges scheduled to run through early ...
Breaking Medicine News(10 mins):